Market News
Tuesday, September 13, 2016
BRIEF-Exelixis says European commission approves Cabometyx
* European Commission approves Cabometyx tablets for the
treatment of advanced renal cell carcinoma following
VEGF-targeted therapy
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment